

CLEVELAND BIOLABS INC  
Form 8-K  
May 09, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of Earliest Event Reported): May 7, 2013**

**Cleveland BioLabs, Inc.**

(Exact Name of Issuer as Specified in Charter)

**DELAWARE**  
(State or Other Jurisdiction of  
Incorporation or Organization)

**001-32954**  
(Commission File Number)

**20-0077155**  
(I.R.S. Employer Identification  
Number)

**73 High Street**  
**Buffalo, NY**  
(Address of Principal Executive Offices)

**(716) 849-6810**  
(Registrant's Telephone Number, Including Area Code)

**14203**  
(Zip Code)

**Not Applicable**  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 

**Item 2.02. Results of Operations and Financial Condition.**

On May 9, 2013, Cleveland BioLabs, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2013. The information in this Item 2.02 of Form 8-K and Exhibit 99.1 attached hereto

shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference.

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On May 7, 2013, the Board of Directors (the "Board") of the Company expanded the size of the Board from nine to ten members and elected Randy S. Saluck as a director of the Company to hold such office until the Company's 2013 Annual Meeting of Stockholders.

Mr. Saluck has been the Managing Member of Mortar Rock Capital Management, LLC and the Portfolio Manager of Mortar Rock Capital LP, a value-oriented investment fund, since 2005. From 2002 to 2005, Mr. Saluck was a portfolio manager at the investment fund of Meisenbach Capital, LP and, from 2000 to 2002, Mr. Saluck was a senior analyst at Tyndall Partners, LLC, which invested in value-oriented equities and distressed debt. From 1999 to 2000, Mr. Saluck was an analyst at Highfields Capital Management, LLC, where he was responsible for special situations and risk arbitrage. Prior thereto, Mr. Saluck was an investment banker focused on mergers and acquisitions involving a variety of industries at Salomon Brothers Inc. Before becoming an investment banker, Mr. Saluck was a corporate and securities attorney, working at Cahill Gordon & Reindel LLP and then Tenzer Greenblatt LLP. As an attorney, Mr. Saluck worked with numerous small capitalization companies assisting them in the execution of their financing and strategic plans. He received a Bachelor's degree from the University of Pennsylvania, a Juris Doctor degree from the University of Virginia and an MBA from the Wharton School of the University of Pennsylvania with a concentration in finance and accounting. Mr. Saluck currently serves on the Board of Directors of the Connecticut Region of the Anti-Defamation League.

In connection with his appointment to the Board, Mr. Saluck was granted an option to purchase 15,000 shares of the Company's common stock. The options will vest in three equal installments on the first, second and third anniversaries of Mr. Saluck's appointment to the Board and will accelerate in full upon a change in control of the Company or upon his death, disability or retirement.

There are no transactions between Mr. Saluck and the Company required to be reported pursuant to Item 404(a) of Regulation S-K.

**Item 9.01. Financial Statements and Exhibits.**

(d)

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated May 9, 2013

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Cleveland BioLabs, Inc.**

Date: May 9, 2013

By: /s/ YAKOV KOGAN

Name: Yakov Kogan, Ph.D., M.B.A.

Title: Chief Executive Officer